Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
about
Cancer pharmacogenomics: strategies and challengesImproved endpoints for cancer immunotherapy trialsQuantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imagingUsing continuous data on tumour measurements to improve inference in phase II cancer studies.Joint model for left-censored longitudinal data, recurrent events and terminal event: Predictive abilities of tumor burden for cancer evolution with application to the FFCD 2000-05 trial.Improving the power of clinical trials of rheumatoid arthritis by using data on continuous scales when analysing response rates: an application of the augmented binary methodValidation of novel imaging methodologies for use as cancer clinical trial end-pointsCD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients.Volumes to learn: advancing therapeutics with innovative computed tomography image data analysis.Melanoma: a model for testing new agents in combination therapies.Designing phase II trials in cancer: a systematic review and guidance.Residual serum monoclonal protein predicts progression-free survival in patients with previously untreated multiple myelomaCancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST.Evaluation of the optimal number of lesions needed for tumor evaluation using the response evaluation criteria in solid tumors: a north central cancer treatment group investigation.A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neckResampling phase III data to assess phase II trial designs and endpoints.Influence of methotrexate exposure on outcome in patients treated with MBVP chemotherapy for primary central nervous system lymphomaResampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trialsPositron Emission Tomography (PET) in OncologyFrom RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer.Randomized phase II trials: a long-term investment with promising returnsVariability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes.Evaluation of RECIST in chemotherapy-treated lung cancer: the Pharmacogenoscan Study.Objective assessment of tumour response to therapy based on tumour growth kinetics.Comparison of continuous versus categorical tumor measurement-based metrics to predict overall survival in cancer treatment trialsClinical trials in the era of personalized oncology.Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741The power of phase II end-points for different possible mechanisms of action of an experimental treatmentClinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods.Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection.Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival.Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling.Simulations to Assess Phase II Noninferiority Trials of Different Doses of Capecitabine in Combination With Docetaxel for Metastatic Breast Cancer.Modeling NSCLC progression: recent advances and opportunities availableAnalysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials.When progressive disease does not mean treatment failure: reconsidering the criteria for progression.A simulation study to evaluate the impact of the number of lesions measured on response assessmentComparison of power between randomized discontinuation design and upfront randomization design on progression-free survival.Novel clinical trial designs for innovative therapies.
P2860
Q24289309-EE90C46C-146D-4365-98C2-F893B8F0767AQ24603112-2D09C6C4-07E1-4A3A-BEA5-854F28EF6F21Q27346895-A1D739F3-93F8-4327-8696-8498CD4BDE98Q30649937-3F606E0A-5708-4F11-BB8A-3674237D02C5Q31047563-B13C11E0-6EFD-4D3E-A119-493BA9A69005Q31110280-D34B9430-61EF-440C-A014-DC822580F501Q33394106-0D25F65B-6FE0-4F0C-A08C-86CC8CB62FB8Q33630819-0EEE4BF4-EC1A-4BFC-A215-3A851A7B2C45Q33636321-F0FAE442-566E-43DE-862A-1FDF3244590CQ33863916-709287C6-22A3-44A0-BC9D-F61BEA1680D5Q33945307-C6907740-3E56-4AA7-9A44-172217667BB2Q34001363-936B4C73-180F-4203-8DCE-3F98AB9BCCEAQ34023973-2C2E9653-1EB8-46D4-BD75-E42629B9D3DCQ34049406-55EB0CB3-B9DE-47F2-8E1E-B539EAABE31CQ34083131-FA8F7624-6DCC-4CC7-9D94-CA38ACA53612Q34144413-5F3B4CF9-0DFC-424D-977F-2F8294B2058FQ34174899-53296495-819B-4EBA-93E3-A34A000DDDE2Q34716556-4BF2E823-9C40-499E-A80F-FB0E1F44E2AAQ34774840-4CDC4577-206D-48E2-8CDF-80A0819440F0Q34978457-55786EC0-8E7B-48AB-98A6-EDC379ECCAC7Q35081379-541E5DDA-38A2-48C8-A5E1-95974E3DC4B3Q35115259-202F5B34-0CF1-4B86-BD47-D192DAF7ED59Q35170251-FC270097-F52F-4443-AD1F-BD7F9929D869Q35190735-4AFB08EA-758A-4BD3-91A6-920A0DEC5EC8Q35287641-70949406-2382-4312-B584-9824837D2C32Q35375761-055B0D4B-905E-4A7B-B2FC-5874794ED6BDQ35555963-87653B12-82C7-498B-8FAC-E6DA17C03AFDQ35584926-B5AD3FC6-810C-4418-AA5A-10DB9FFDA19EQ35619065-4C9E6EB7-F947-4837-A2A9-045AFC1F684CQ35821903-16666E80-D5F9-4583-AD6C-6EB21A1F8AE9Q35914787-C7440A82-4FDE-4BB6-9CD3-AE2CF5804BDBQ36276553-988CC442-CAA9-47C5-AF62-A54A5BCD4CE8Q36599208-46894F5F-E133-41EF-B423-410E24CB14B7Q36693695-A97FC599-03B7-486B-B999-3312C217902BQ36910615-29C89868-AD94-4B38-A5C8-225EB04009F7Q36914483-EF56E204-ACDE-4FFF-B319-D421275C4FC6Q37003248-690D1EF8-8CAE-48A1-B566-77B9B8154849Q37121048-5C8844DE-75D8-49FB-9DC4-DA389A94F410Q37325089-4EEAFAC1-8326-4E44-A33C-76D92E035C4AQ37358492-29760D60-6344-4EF2-AB77-DD9BC1B701C7
P2860
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Design of phase II cancer tria ...... in non small-cell lung cancer.
@en
Design of phase II cancer tria ...... in non small-cell lung cancer.
@nl
type
label
Design of phase II cancer tria ...... in non small-cell lung cancer.
@en
Design of phase II cancer tria ...... in non small-cell lung cancer.
@nl
prefLabel
Design of phase II cancer tria ...... in non small-cell lung cancer.
@en
Design of phase II cancer tria ...... in non small-cell lung cancer.
@nl
P2093
P2860
P356
P1476
Design of phase II cancer tria ...... in non small-cell lung cancer.
@en
P2093
Michael L Maitland
Theodore G Karrison
Walter M Stadler
P2860
P304
P356
10.1093/JNCI/DJM158
P407
P577
2007-09-25T00:00:00Z